BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price, Forecast & Analysis
NASDAQ:BDTX • US09203E1055
BDTX Key Statistics, Chart & Performance
The current stock price of BDTX is 2.55 USD. In the past month the price decreased by -0.39%. In the past year, price increased by 26.87%.
BDTX Technical Analysis
BDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BDTX. While BDTX has a great health rating, its profitability is only average at the moment.
BDTX Financial Highlights
Over the last trailing twelve months BDTX reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 127.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.69% | ||
| ROA | 13.62% | ||
| ROE | 17.03% | ||
| Debt/Equity | 0 |
BDTX Forecast & Estimates
15 analysts have analysed BDTX and the average price target is 9.31 USD. This implies a price increase of 265% is expected in the next year compared to the current price of 2.55.
BDTX Ownership
BDTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 403.74B | ||
| AMGN | AMGEN INC | 16.99 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.83 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Company Info
BLACK DIAMOND THERAPEUTICS I
245 First Street, 18Th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 24
Phone: 16174175868
BLACK DIAMOND THERAPEUTICS I / BDTX FAQ
Can you describe the business of BLACK DIAMOND THERAPEUTICS I?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
What is the current price of BDTX stock?
The current stock price of BDTX is 2.55 USD. The price increased by 5.81% in the last trading session.
Does BLACK DIAMOND THERAPEUTICS I pay dividends?
BDTX does not pay a dividend.
How is the ChartMill rating for BLACK DIAMOND THERAPEUTICS I?
BDTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is BLACK DIAMOND THERAPEUTICS I (BDTX) stock traded?
BDTX stock is listed on the Nasdaq exchange.
What do analysts say about BLACK DIAMOND THERAPEUTICS I (BDTX) stock?
15 analysts have analysed BDTX and the average price target is 9.31 USD. This implies a price increase of 265% is expected in the next year compared to the current price of 2.55.